Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy

被引：15

作者：

Yamamura, Kensuke ^{[1
,2
]}

Beppu, Toru ^{[1
,2
]}

Miyata, Tatsunori ^{[2
]}

Okabe, Hirohisa ^{[2
]}

Nitta, Hidetoshi ^{[2
]}

Imai, Katsunori ^{[2
]}

Hayashi, Hiromitsu ^{[2
]}

Akahoshi, Shinichi ^{[1
,2
]}

机构：

[1] Yamaga City Med Ctr, Dept Surg, Yamaga, Japan

[2] Kumamoto Univ, Grad Sch Life Sci, Dept Surg Gastroenterol, Kumamoto, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 01期

关键词：

Conversion hepatectomy; surgery; hepatocellular; carcinoma; lenvatinib; molecular therapy; review; ATEZOLIZUMAB PLUS BEVACIZUMAB; CANCER STUDY-GROUP; CLINICAL PHARMACOKINETICS; LENVATINIB TREATMENT; 1ST-LINE TREATMENT; COMPLETE RESPONSE; LIVER RESECTION; SALVAGE SURGERY; SORAFENIB; HEPATECTOMY;

D O I：

10.21873/anticanres.15454

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Novel molecular therapies using targeted drugs and immune checkpoint inhibitors for advanced hepatocellular carcinoma have been evolving. Sorafenib and lenvatinib have been commonly used as first-line therapy, followed by recent atezolizumab plus bevacizumab. The median survival time has gradually improved to over 1.5 years. The complete radiological response does not always mean a complete pathological response and a permanent cure of disease. To resolve this, conversion surgery has developed. Lenvatinib is the most suitable drug due to its high response rate. A recent large cohort study using lenvatinib had a conversion rate of 8.4% and an estimated disease-specific survival time of >80% at three years. Conversion to curative resection was an independent predictive factor for better disease-specific survival compared with lenvatinib monotherapy. In conclusion, conversion surgery following molecular therapy is a promising treatment strategy for prolonging long-term outcomes. We should discuss promising drugs and the timing for conversion surgery.

引用

页码：35 / 44

页数：10

共 65 条

[1] FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma [J].

Arao, Tokuzo ;

Ueshima, Kazuomi ;

Matsumoto, Kazuko ;

Nagai, Tomoyuki ;

Kimura, Hideharu ;

Hagiwara, Satoru ;

Sakurai, Toshiharu ;

Haji, Seiji ;

Kanazawa, Akishige ;

Hidaka, Hisashi ;

Iso, Yukihiro ;

Kubota, Keiichi ;

Shimada, Mitsuo ;

Utsunomiya, Tohru ;

Hirooka, Masashi ;

Hiasa, Yoichi ;

Toyoki, Yoshikazu ;

Hakamada, Kenichi ;

Yasui, Kohichiroh ;

Kumada, Takashi ;

Toyoda, Hidenori ;

Sato, Shuichi ;

Hisai, Hiroyuki ;

Kuzuya, Teiji ;

Tsuchiya, Kaoru ;

Izumi, Namiki ;

Arii, Shigeki ;

Nishio, Kazuto ;

Kudo, Masatoshi .

HEPATOLOGY, 2013, 57 (04) :1407-1415

[2] Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab [J].

Aussilhou, Beatrice ;

Dokmak, Safi ;

Faivre, Sandrine ;

Paradis, Valerie ;

Vilgrain, Valerie ;

Belghiti, Jacques .

ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (06) :1553-1559

[3]

Beckwith C, 2007, CANC CHEMOTHERAPY MA

[4] Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma [J].

Briggs, Andrew ;

Daniele, Bruno ;

Dick, Katherine ;

Evans, Thomas R. Jeffry ;

Galle, Peter R. ;

Hubner, Richard A. ;

Lopez, Carlos ;

Siebert, Uwe ;

Tremblay, Gabriel .

BRITISH JOURNAL OF CANCER, 2020, 122 (12) :1754-1759

[5] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial [J].

Bruix, Jordi ;

Takayama, Tadatoshi ;

Mazzaferro, Vincenzo ;

Chau, Gar-Yang ;

Yang, Jiamei ;

Kudo, Masatoshi ;

Cai, Jianqiang ;

Poon, Ronnie T. ;

Han, Kwang-Hyub ;

Tak, Won Young ;

Lee, Han Chu ;

Song, Tianqiang ;

Roayaie, Sasan ;

Bolondi, Luigi ;

Lee, Kwan Sik ;

Makuuchi, Masatoshi ;

Souza, Fabricio ;

Le Berre, Marie-Aude ;

Meinhardt, Gerold ;

Llovet, Josep M. .

LANCET ONCOLOGY, 2015, 16 (13) :1344-1354

[6] Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report [J].

Chen, Xin ;

Zhang, Yazhou ;

Zhang, Nu ;

Ge, Yongsheng ;

Jia, Weidong .

ONCOTARGETS AND THERAPY, 2019, 12 :7355-7359

[7] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[8] Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis [J].

Chuma, Makoto ;

Uojima, Haruki ;

Hiraoka, Atsushi ;

Kobayashi, Satoshi ;

Toyoda, Hidenori ;

Tada, Toshifumi ;

Hidaka, Hisashi ;

Iwabuchi, Shogo ;

Numata, Kazushi ;

Itobayashi, Ei ;

Itokawa, Norio ;

Kariyama, Kazuya ;

Ohama, Hideko ;

Hattori, Nobuhiro ;

Hirose, Shunji ;

Shibata, Hiroshi ;

Tani, Joji ;

Imai, Michitaka ;

Tajiri, Kazuto ;

Moriya, Satoshi ;

Wada, Naohisa ;

Iwasaki, Shuitirou ;

Fukushima, Taito ;

Ueno, Makoto ;

Yasuda, Satoshi ;

Atsukawa, Masanori ;

Nouso, Kazuhiro ;

Fukunishi, Shinya ;

Watanabe, Tsunamasa ;

Ishikawa, Toru ;

Nakamura, Shinichiro ;

Morimoto, Manabu ;

Kagawa, Tatehiro ;

Sakamoto, Michiie ;

Kumada, Takashi ;

Maeda, Shin .

HEPATOLOGY RESEARCH, 2021, 51 (02) :201-215

[9] Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case Report [J].

Curtit, Elsa ;

Thiery-Vuillemin, Antoine ;

Nguyen, Thierry ;

Heyd, Bruno ;

Pivot, Xavier ;

Di Martino, Vincent ;

Borg, Christophe .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :E330-E332

[10] A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario [J].

Dipasquale, Angelo ;

Marinello, Arianna ;

Santoro, Armando .

JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 :241-251

← 1 2 3 4 5 6 7 →